soul trial oral semaglutide cardiovascular outcomes results 2024 2025 reduces risk of events Oral Semaglutide and Cardiovascular Outcomes

Compounded medications can be used when FDA-approved drugs are in short supply

Individuals should consult their healthcare practitioner before starting any new supplement regimen

[94] found that patients who were treated with GLP-1RAs after a heart attack related PCI, showed improved LVEF and reduced infarct size

All handling, storage, and experimental procedures must comply with applicable scientific research guidelines and institutional laboratory standards

This study aimed to critically assess the existing literature on the adverse effects of GLP-1 RAs to formulate appropriate risk-benefit prescription practices for their optimal utilization as metabolic disease therapeutics